![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, October 30, 2011 12:10:24 AM
BACTERIAL INFECTIONS AND DETERMINE ANTIBIOTIC RESISTANCE
Raman spectroscopy technique may lead to more effective treatment for
patients with Staph infections
SAN FRANCISCO—Surgeons at Detroit Medical Center and Wayne State University in Detroit are developing a faster, less expensive method of identifying bacterial infections and determining their antibiotic resistance. Surgeons used a technology known as Raman spectroscopy to look at the bacteria’s infrared wavelengths and pinpoint unique patterns of molecular vibration in blood samples inoculated with Staphylococcus aureus, the bacteria that causes Staph infections. Their findings were reported today at the 2011 Annual Clinical Congress of the American College of Surgeons.
The study, led by Amy Riley Spencer, MD, general surgery resident at Detroit Medical Center and Wayne State University, observed 120 spectral patterns from four strains of antibiotic resistant S. aureus: two that were sensitive to the antibiotic methicillin, one that was resistant to methicillin, and a more stubborn form of Staph infection that has a reduced susceptibility to a last-resort antibiotic called vancomycin (RVS-MRSA).
Raman spectroscopy enabled the researchers to distinguish the methicillin sensitive S. aureus (MSSA) from methicillin resistant S. aureus (MRSA) with 90.2 percent accuracy. They also could tell the difference between MRSA and its more stubborn form, RVS-MRSA, with 96.3 percent accuracy. The S. aureus profiles were then entered into a statistical program to create a preformed model of the Raman spectra. When the surgeons tested new spectra, the program was 98 percent accurate in classifying the bacteria as one of the four strains.
Based on these results, the researchers believe the Raman spectroscopy technique could lead to the development of faster, more effective treatment for people with Staph infections. Currently, emergency room patients may have to wait about six hours before diagnostic tests can identify a Staph infection and another 24 to 72 hours to determine which antibiotics could treat it, said Dr. Spencer. In the meantime, “you treat these very sick patients with the antibiotics you have and hope that will control it. The overuse of such antibiotics has been blamed for the rise of antibiotic resistance. This scenario could lead to a situation where the bacterial infection can’t be treated. Our findings suggest that Raman spectroscopy can identify the infection earlier and save money by treating the infection quicker instead of hoping an antibiotic is working and then switching when it doesn’t,” Dr. Spencer explained.
The S. aureus profiles generated by Raman spectroscopy are among dozens of pathogen profiles being added to a database of other bacteria, viruses, malignant tumors, and fungi. “Our goal is to map out as complete a number of pathogens and pathogenic organisms as we can, starting with the most pertinent ones first and, as we get further into it, the ones you don’t see very often,” Dr. Spencer said. In early 2012, Dr. Spencer and her team expect to launch a clinical trial comparing Raman spectroscopy with traditional identification techniques with funding from the National Institutes of Health and Wayne State University.
Researchers are simultaneously developing a technology to integrate the pathogen database and the Raman spectroscopy technique into a hand-held device that would cut turnaround times for diagnostic test results from several hours to about 10 minutes. Currently, Raman spectroscopy is deployed through costly table-top devices and portable robots, said Gregory Auner, PhD, a professor in the department of electrical and computer engineering and founder and director of the Smart Sensors and Integrated Microsystems Program at Wayne State University.
“We are miniaturizing it even further, down to the size of two or three cell phones,” said Dr. Auner, who has led the hand-held device’s development for the last five years with grants from the U.S. Department of Defense and the National Institutes of Health. “Also, the price would be two orders of magnitude less, in the thousands of dollars,” he concluded.
Michael D. Klein MD, FACS; Jocelyn Y. Ang, MD; Tara A. Twomey, MS; David J. Sant, BSc; Chantelle N. Chinkhota, PhD; and Rachel E. Kast, PhD, also participated in the study.
# # #
Recent AEMD News
- Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys • PR Newswire (US) • 08/27/2024 12:01:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2024 08:34:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/15/2024 08:32:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/15/2024 08:30:33 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 08/15/2024 08:15:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:10:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:15:21 PM
- Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update • PR Newswire (US) • 08/14/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:01:08 PM
- Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 08/12/2024 12:01:00 PM
- Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024 • PR Newswire (US) • 08/06/2024 01:12:00 PM
- Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update • PR Newswire (US) • 06/27/2024 08:15:00 PM
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024 • PR Newswire (US) • 06/21/2024 12:01:00 PM
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 06/18/2024 12:01:00 PM
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies • PR Newswire (US) • 06/03/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 05:24:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:05:28 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/16/2024 08:05:23 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/15/2024 01:27:15 PM
- Aethlon Medical Announces Pricing of $4.7 Million Public Offering • PR Newswire (US) • 05/15/2024 01:15:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/13/2024 09:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 12:01:40 PM
FEATURED Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • Sep 4, 2024 9:02 AM
FEATURED Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • Sep 4, 2024 8:45 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM
PickleJar Launches National "Get on the Bus" Campaign, Unveils Thompson Square Tour Bus Wrap • PKLE • Sep 4, 2024 7:17 AM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM